Vigonvita Life Sciences (旺山旺水) Pre-IPO: Window Dressing
Vigonvita aims to raise over US$100 million in Hong Kong listing with CITIC as book runner. In this note we note the company dropped anti-viral...
471 Views
Pre-IPO Vigonvita Life Sciences (PHIP Updates) - Some Points Worth the Attention
Vigonvita's short-term product revenue outlook is uncertain, with concerns on IPO fundraising rational.If TPN171 sales is poor or clinical trial...
430 Views
APAC Healthcare Weekly (March 29) – Hansoh, CSPC, Chugai, Takeda, Otsuka, Celltrion, Alteogen
Hansoh got trial approval, while CSPC obtained new drug approval. Chugai’s partner is discontinuing development of emugrobart. Otsuka is acquiring...
336 Views
APAC Healthcare Weekly (December 7) – Simcere, Kelun Bio, Samsung Biologics, Daiichi Sankyo, Biocon
Simcere stuck license pact with Vigonvita. Kelun Bio inked partnership with Crescent Biopharma. Samsung Biologics is acquiring land for third...
634 Views
Hong Kong: IPO SPOTLIGHT - OVERVIEW 2025
Hong Kong is the top global destination for IPOs in 2025, with over HK $280 billion raised so far. Large scale A+H dual listings have surged this...
961 Views